BioCentury
ARTICLE | Top Story

Amgen partners five mAbs with AZN

April 3, 2012 1:09 AM UTC

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to jointly develop and commercialize five of Amgen's mAbs in its inflammation portfolio. The deal includes anti- IL17R mAb brodalumab (formerly AMG 827), which is slated to begin Phase III testing this year for psoriasis. Brodalumab is also in Phase II testing for psoriatic arthritis and asthma. Last week, Amgen said brodalumab met the primary endpoint in a Phase II trial to treat psoriasis (see BioCentury Extra, March 28).

The other products are: AMG 139, an undisclosed mAb in Phase Ib testing for Crohn's disease; AMG 157, a mAb that blocks interaction of thymic stromal lymphopoietin (TSLP) with TSLP receptor in Phase Ib testing for asthma and atopic dermatitis; AMG 181, an undisclosed mAb in Phase Ib testing for ulcerative colitis and Crohn's disease; and AMG 557, a mAb targeting B7 related protein 1 (B7RP-1) in Phase I testing for systemic lupus erythematosus (SLE). ...